全文获取类型
收费全文 | 523篇 |
免费 | 24篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 29篇 |
妇产科学 | 4篇 |
基础医学 | 50篇 |
口腔科学 | 28篇 |
临床医学 | 46篇 |
内科学 | 99篇 |
皮肤病学 | 5篇 |
神经病学 | 5篇 |
特种医学 | 108篇 |
外科学 | 61篇 |
综合类 | 9篇 |
预防医学 | 35篇 |
眼科学 | 2篇 |
药学 | 29篇 |
中国医学 | 2篇 |
肿瘤学 | 53篇 |
出版年
2022年 | 2篇 |
2019年 | 12篇 |
2018年 | 8篇 |
2017年 | 6篇 |
2016年 | 9篇 |
2015年 | 11篇 |
2014年 | 8篇 |
2013年 | 23篇 |
2012年 | 6篇 |
2011年 | 7篇 |
2010年 | 25篇 |
2009年 | 27篇 |
2008年 | 8篇 |
2007年 | 16篇 |
2006年 | 10篇 |
2005年 | 12篇 |
2004年 | 16篇 |
2003年 | 6篇 |
2002年 | 10篇 |
2001年 | 4篇 |
2000年 | 7篇 |
1999年 | 11篇 |
1998年 | 29篇 |
1997年 | 36篇 |
1996年 | 29篇 |
1995年 | 27篇 |
1994年 | 24篇 |
1993年 | 18篇 |
1992年 | 12篇 |
1991年 | 7篇 |
1990年 | 9篇 |
1989年 | 18篇 |
1988年 | 17篇 |
1987年 | 10篇 |
1986年 | 17篇 |
1985年 | 12篇 |
1984年 | 7篇 |
1983年 | 8篇 |
1982年 | 15篇 |
1981年 | 7篇 |
1980年 | 5篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1975年 | 6篇 |
1941年 | 1篇 |
排序方式: 共有566条查询结果,搜索用时 31 毫秒
1.
D L Lamm J I DeHaven J Shriver R Crispen D Grau M F Sarosdy 《The Journal of urology》1990,144(1):65-67
Reports of a dramatic decrease in tumor recurrence and regression of muscle invasive disease with oral bacillus Calmette-Guerin prompted us to conduct a randomized prospective comparison of oral bacillus Calmette-Guerin with the standard intravesical plus percutaneous therapy. Oral therapy consisted of 200 mg. Tice bacillus Calmette-Guerin 3 times each week. Intravesical and percutaneous Tice bacillus Calmette-Guerin at a dose of 50 mg. was given weekly for 6 weeks, at 8, 10 and 12 weeks, then at 6 months and every 6 months thereafter. Minimal side effects confirmed the safety of oral bacillus Calmette-Guerin. Tumor recurrence was documented in 21 of 33 oral bacillus Calmette-Guerin patients (64%) and 18 of 55 (33%) who received intravesical plus percutaneous therapy (p less than 0.002, chi-square test). We were unable to demonstrate any antitumor activity of oral bacillus Calmette-Guerin in this study. 相似文献
2.
Principles of intravesical chemotherapy and immunotherapy. 总被引:2,自引:0,他引:2
M F Sarosdy 《The Urologic clinics of North America》1992,19(3):509-519
By tailoring the use and selection of an intravesical agent to the individual patient, it should be possible to reduce toxicity and avoid overtreatment. Similarly, patients with more alarming disease processes can be treated sooner if the need for that more aggressive or toxic therapy is recognized early. Finally, it is important to recognize that patients who fail initial therapy with BCG have a good probability of responding to additional BCG and that there are promising investigational immunotherapies available for those who fail adequate courses of BCG. 相似文献
3.
B L Neubauer K L Best R L Goode M L Heiman D M Hoover D W Robertson M F Sarosdy C J Shaar L R Tanzer R L Merriman 《Cancer research》1992,52(17):4663-4671
The effects of hormonal ablation, estrogen, estrogen-derived cytotoxic agent, and estrogen antagonist therapies used clinically were evaluated on in vitro colony formation, in vivo growth, and lymphatic and pulmonary metastasis of the PAIII tumor. Ventral prostatic and seminal vesicle weights were evaluated in the same animals to assess androgen-related responses. Estradiol, estramustine phosphate, and testosterone had no effects on PAIII colony formation in vitro. Castration, hypophysectomy, estradiol benzoate, and estramustine phosphate treatment of PAIII-bearing Lobund Wistar rats produced significant (P less than 0.05) regression of male accessory sex organs. Of these treatments, only hypophysectomy had significant (P less than 0.05) inhibitory effects on primary PAIII growth and lymphatic and pulmonary metastasis. LY117018 [6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-2-(l-pyrrolidin yl)ethoxy phenyl ketone] has antiestrogenic activity but produces no significant agonist responses. LY117018 had no effect upon PAIII colony formation in vitro. Following s.c. implantation of PAIII cells, LY117018 (2.0, 10.0, or 20.0 mg/kg s.c.) had no effect on primary tumor growth in the tail. In vitro LY117018 administration produced marked antimetastatic effects. In a dose-dependent manner, LY117018 inhibited PAIII metastasis to the gluteal (97%) and iliac lymph nodes (88%) (P less than 0.05 for both). LY117018 also maximally inhibited pulmonary metastasis by 86% (P less than 0.05). Maximal regression of 42% for ventral prostatic and 35% for seminal vesicle weights were also seen after LY117018 administration (P less than 0.05 for both). Co-administration of estradiol benzoate had no antagonistic effect upon the antitumor responses produced by LY117018. The mechanism of action of LY117018 is not known. The failure of estradiol benzoate to affect PAIII growth and metastasis supports the contention that the responses to LY117018 are not attributable to simple antagonism of estrogen action. LY117018 may be exerting its antitumor effects through autocrine, paracrine, or endocrine mechanisms. LY117018 represents a class of agents with potential utility in treating metastatic cancer of the prostate. 相似文献
4.
Michael F. Sarosdy 《World journal of urology》1997,15(2):103-106
Summary The BTA Test is an adjunctive test for the diagnosis and management of bladder cancer. For estimation of its potential in the management of patients with transitional-cell cancer (TCC) a review of published results was undertaken. Three prospective studies were analyzed, in which a total of 699 patients with a history of TCC were enrolled. The BTA Test was performed on voided urine and compared with either voided-urine or bladder-wash cytologic analysis in a blinded fashion. In all three studies the sensitivity of the BTA Test was more than double that of cytology, irrespective of whether the cytologic analysis was performed on voided or bladder-wash samples. The third study also included an additional 225 patients undergoing evaluation for hematuria, and TCC was found in 67 cases. The BTA Test detected 70% of these tumors, whereas cytology detected only 25%. The BTA Test is a simple, rapid test that can diagnose a substantial percentage of patients having new or recurrent bladder TCC. Its complete role in the management of such patients remains to be defined. 相似文献
5.
6.
Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer 总被引:3,自引:0,他引:3
W H Rawls D L Lamm B A Lowe E D Crawford M F Sarosdy J E Montie H B Grossman P T Scardino 《The Journal of urology》1990,144(6):1328-1330
Intravesical administration of bacillus Calmette-Guerin has been shown to be highly effective treatment of superficial bladder cancer. Complications from bacillus Calmette-Guerin therapy are usually minor but serious and even fatal reactions can occur. Five recent cases illustrate the gravity of bacillus Calmette-Guerin sepsis. One man with severe debility and the organic brain syndrome died acutely with a fever of 40 C. Two men had frank sepsis that progressed to multiorgan failure and death. Sepsis progressed despite the use of isoniazid, rifampin and streptomycin. Two men who had equally progressive sepsis with intravesical bacillus Calmette-Guerin survived with the use of cycloserine for the first 72 hours of treatment. Triple antituberculous antibiotics, including cycloserine, may be lifesaving. Sepsis resulted from intravenous absorption through inflamed or disrupted urothelium. Bacillus Calmette-Guerin treatment should not be administered in the presence of severe cystitis or after grossly traumatic catheterization. 相似文献
7.
Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience 总被引:14,自引:0,他引:14
8.
9.
10.
Predominance of null mutations in ataxia-telangiectasia 总被引:15,自引:4,他引:15
Gilad S; Khosravi R; Shkedy D; Uziel T; Ziv Y; Savitsky K; Rotman G; Smith S; Chessa L; Jorgensen TJ; Harnik R; Frydman M; Sanal O; Portnoi S; Goldwicz Z; Jaspers NG; Gatti RA; Lenoir G; Lavin MF; Tatsumi K; Wegner RD; Shiloh Y; Bar-Shira A 《Human molecular genetics》1996,5(4):433-439
Ataxia-telangiectasia (A-T) is an autosomal recessive disorder involving
cerebellar degeneration, immunodeficiency, chromosomal instability,
radiosensitivity and cancer predisposition. The responsible gene, ATM, was
recently identified by positional cloning and found to encode a putative
350 kDa protein with a Pl 3-kinase-like domain, presumably involved in
mediating cell cycle arrest in response to radiation-induced DNA damage.
The nature and location of A-T mutations should provide insight into the
function of the ATM protein and the molecular basis of this pleiotropic
disease. Of 44 A-T mutations identified by us to date, 39 (89%) are
expected to inactivate the ATM protein by truncating it, by abolishing
correct initiation or termination of translation, or by deleting large
segments. Additional mutations are four smaller in-frame deletions and
insertions, and one substitution of a highly conserved amino acid at the Pl
3-kinase domain. The emerging profile of mutations causing A-T is thus
dominated by those expected to completely inactivate the ATM protein. ATM
mutations with milder effects may result in phenotypes related, but not
identical, to A-T.
相似文献